研究单位：[1]Qilu Pharmaceutical Co.,Ltd.[2]Sichuan Cancer Hospital Chengdu,Sichuan,China,610041
研究目的：
This study is designed to evaluate the safety and tolerability of QLF31907 injection,to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT),and determine the recommended phase Ib dose(RPIbD) and recommended phase II dose (RP2D)in patients with advanced malignant tumors.
